Impax Laboratories will collaborate with Perrigo on the development, manufacturing, and commercialization of an extended topical generic drug product with first-to-market potential.
“In just over two years, Impax has partnered with four different companies on 27 alternative dosage form products, with 18 of these either pending approval at the U.S. Food and Drug Administration or under development,” says Larry Hsu, Ph.D., president and CEO of Impax. “We will continue to focus on delivering growth from high-value products, technologies, and businesses in complementary dosage forms.”
“This collaboration is yet another example of our long-term investment in development of products in the extended topical space,” adds Perrigo’s chairman, president, and CEO, Joseph C. Papa.
Impax applies its formulation knowledge and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax claims to currently manufacture and market 102 generic pharmaceutical products, which represent dosage variations of 30 different pharmaceutical compounds. The firm’s branded pipeline is focused on targeting significant unmet needs in the CNS market including Parkinson’s disease, restless legs syndrome, and spasticity in patients with multiple sclerosis.
Perrigo develops, manufactures, and distributes over the counter and generic prescription pharmaceuticals, nutritional products, and active pharmaceutical ingredients.